News

Pharmabiz6m
Nuravax, Institute for Molecular Medicine to present phase 1 results & phase 2 design of Alzheimer’s vaccine AV-1959R at CTAD 2025
Nuravax, Institute for Molecular Medicine to present phase 1 results & phase 2 design of Alzheimer’s vaccine AV-1959R at CTAD 2025: Irvine, California Friday, July 4, 2025, 17:0 ...
Pharmabiz4h
Pharmac South 2025 opened at Chennai Trade Centre today
Our Bureau, Chennai Friday, July 4, 2025, 12:45 Hrs [IST] Pharmac South 2025, the 10th edition of South India's high-power ...
Pharmabiz1h
PHARMASEAL announces Technical Integration Partnership with Viedoc
PHARMASEAL announces Technical Integration Partnership with Viedoc: Nottingham, UK Friday, July 4, 2025, 16:00 Hrs [IST] PHARMASEAL, provider of the Engility Trial Management Plat ...
Pharmabiz2h
Inmagene enrolls first patient in ADAPTIVE phase 2b clinical trial of IMG-007
Inmagene enrolls first patient in ADAPTIVE phase 2b clinical trial of IMG-007: San Diego Friday, July 4, 2025, 15:00 Hrs [IST] Inmagene Biopharmaceuticals (Inmagene), a clinical-s ...
Pharmabiz23h
KSPC launches maiden virtual simulation-based pharma manufacturing training programme
KSPC launches maiden virtual simulation-based pharma manufacturing training programme: Our Bureau, Bengaluru Thursday, July 3 ...
Pharmabiz4h
Jacobio Pharma submits phase I/II IND application for its BET inhibitor, JAB-8263 to treat autoimmune diseases to CDE in China
Jacobio Pharma submits phase I/II IND application for its BET inhibitor, JAB-8263 to treat autoimmune diseases to CDE in China: Beijing, Shanghai Friday, July 4, 2025, 13:00 Hrs [ ...
Pharmabiz3h
Sunshine Biopharma’s Canadian subsidiary, Nora Pharma launches biosimilar drug, Niopeg
Sunshine Biopharma’s Canadian subsidiary, Nora Pharma launches biosimilar drug, Niopeg: Fort Lauderdale, Florida Friday, July 4, 2025, 14:00 Hrs [IST] Sunshine Biopharma Inc., a ...
Pharmabiz5h
NS Pharma announces alliance with Boston Children’s Hospital to develop new therapies for rare diseases
NS Pharma announces alliance with Boston Children’s Hospital to develop new therapies for rare diseases: Paramus, New Jersey Friday, July 4, 2025, 12:00 Hrs [IST] Paramus-headqu ...
Pharmabiz7h
SonoClear receives US FDA breakthrough designation for its SonoClear system for use in intracranial ultrasound procedures
SonoClear receives US FDA breakthrough designation for its SonoClear system for use in intracranial ultrasound procedures: Oslo, Norway Friday, July 4, 2025, 10:00 Hrs [IST] SonoC ...
Pharmabiz6h
US FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumours
US FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumours: Dallas Friday, July 4, 2025, ...
Pharmabiz5h
Zyla Health expands in Southeast Asia, empowering patients with personalised digital therapeutics
Zyla Health expands in Southeast Asia, empowering patients with personalised digital therapeutics: Our Bureau, Mumbai Friday, July 4, 2025, 11:30 Hrs [IST] Zyla Health, India’s ...
Pharmabiz8h
Novartis announces top-line results from phase III GCAptAIN study of Cosentyx in giant cell arteritis
Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...